Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway.
Diabetes mellitus accelerates cardiovascular microangiopathies and atherosclerosis, which are a consequence of hyperglycemia. The aldose reductase (AR) polyol pathway contributes to these microvascular complications, but how it mediates vascular damage in response to hyperglycemia is less understood. The RUNX2 transcription factor, which is repressed in diabetic animals, promotes vascular endothelial cell (EC) migration, proliferation, and angiogenesis. Here we show that physiological levels of glucose (euglycemia) increase RUNX2 DNA binding and transcriptional activity, whereas hyperglycemia does not. However, inhibition of AR reverses hyperglycemic suppression of RUNX2. IGF-1 secretion and IGF receptor phosphorylation by autocrine IGF-1 occur equally in euglycemic or hyperglycemic conditions, suggesting that reduced RUNX2 activity in response to hyperglycemia is not because of altered IGF-1/IGF receptor activation. AR also negatively regulates RUNX2-dependent vascular remodeling in an EC wounded monolayer assay, which is reversed by specific AR inhibition in hyperglycemia. Thus, euglycemia supports RUNX2 activity and promotes normal microvascular EC migration and wound healing, which are repressed under hyperglycemic conditions through the AR polyol pathway.
D'Souza
David R
DR
Department of Pathology, Graduate Program in Life Sciences, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, USA.
Salib
Maryann M
MM
Bennett
Jessica
J
Mochin-Peters
Maria
M
Asrani
Kaushal
K
Goldblum
Simeon E
SE
Renoud
Keli J
KJ
Shapiro
Paul
P
Passaniti
Antonino
A
D000449:Aldehyde Reductase / Q000378:metabolism*; D002478:Cells, Cultured; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics / Q000378:metabolism*; D042783:Endothelial Cells / Q000166:cytology / Q000502:physiology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism* / Q000473:pathology; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D018384:Oxidative Stress / Q000502:physiology; D034741:RNA, Small Interfering; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D015533:Transcriptional Activation / Q000187:drug effects / Q000502:physiology; D014945:Wound Healing / Q000502:physiology*
D050659:Core Binding Factor Alpha 1 Subunit; D034741:RNA, Small Interfering; C493709:RUNX2 protein, human; D007334:Insulin-Like Growth Factor I; D000449:Aldehyde Reductase; D017526:Receptor, IGF Type 1; D048049:Extracellular Signal-Regulated MAP Kinases; D005947:Glucose